Paper42547263
Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias.
Iemura T and 10 others. J Immunother Cancer, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias. Papers, record 42547263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42547263
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, OX40 | Major topic |
| Single-Domain Antibodies | Major topic |
| Epitopes | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Epitope Mapping | |
| Female | |
| Immunotherapy |
Source PubMed
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38653243 | Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors. | Cell Chem Biol | 2024 | https://conductscience.org/library/papers/38653243 | PubMed |
| 2 | 40535010 | On the origin of non-specific binders isolated in the selection of phage display peptide libraries. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40535010 | PubMed |
| 3 | 8520220 | NMRPipe: a multidimensional spectral processing system based on UNIX pipes. | J Biomol NMR | 1995 | https://conductscience.org/library/papers/8520220 | PubMed |
| 4 | 32816951 | Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32816951 | PubMed |
| 5 | 29985974 | Noise peak filtering in multi-dimensional NMR spectra using convolutional neural networks. | Bioinformatics | 2018 | https://conductscience.org/library/papers/29985974 | PubMed |
| 6 | 41041320 | Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41041320 | PubMed |
| 7 | 8642328 | The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. | J Exp Med | 1996 | https://conductscience.org/library/papers/8642328 | PubMed |
| 8 | 25484045 | Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. | MAbs | 2014 | https://conductscience.org/library/papers/25484045 | PubMed |
| 9 | 36316061 | First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/36316061 | PubMed |
| 10 | 35794202 | A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. | Commun Biol | 2022 | https://conductscience.org/library/papers/35794202 | PubMed |
| 11 | 25801209 | Combined automated NOE assignment and structure calculation with CYANA. | J Biomol NMR | 2015 | https://conductscience.org/library/papers/25801209 | PubMed |
| 12 | 18490723 | Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. | J Immunol | 2008 | https://conductscience.org/library/papers/18490723 | PubMed |
| 13 | 22911360 | NMR View: A computer program for the visualization and analysis of NMR data. | J Biomol NMR | 1994 | https://conductscience.org/library/papers/22911360 | PubMed |
| 14 | 33148673 | OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33148673 | PubMed |
| 15 | 36927527 | First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/36927527 | PubMed |
| 16 | 40404202 | INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40404202 | PubMed |
| 17 | 35699599 | First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35699599 | PubMed |
| 18 | 19548092 | TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. | J Biomol NMR | 2009 | https://conductscience.org/library/papers/19548092 | PubMed |
| 19 | 2180570 | Amplified and rearranged bcl-2 gene in two lymphoma cell lines, FL-218 and FL-318, carrying a 14;18 translocation. | Cancer Res | 1990 | https://conductscience.org/library/papers/2180570 | PubMed |
| 20 | 20307208 | Control of immunity by the TNFR-related molecule OX40 (CD134). | Annu Rev Immunol | 2010 | https://conductscience.org/library/papers/20307208 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42547263
GET https://conductscience.org/api/papers/v1/42547263/references?page=2